WallStSmart
XRTX

XORTX Therapeutics Inc

NASDAQ: XRTX · HEALTHCARE · BIOTECHNOLOGY

$1.04
-5.45% today

Updated 2026-11-16

Market cap
$1.78M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.61
Dividend yield
—
52W range
$1 – $4
Volume
1.0M

WallStSmart proprietary scores

24
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D
4.8
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-14.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →253 stocks currently score above 75

Price targets

Analyst target
$14.04
+1250.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -14.19 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.34M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-10.45M$-2.16M$-3.15M$-2.66M$-1.69M
EPS————$-2.61
Free cash flow$-8.21M$-6.63M$-3.72M$-2.82M$-6.34M
Profit margin—————

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
XRTX$1.78M243.73.05.04.8—Avoid
LLY$1.27T749.310.05.06.0—Strong Buy
JNJ$682.52B544.78.53.75.5—Buy
ABBV$520.47B776.79.04.05.0-87.62%Strong Buy
UNH$363.01B626.76.04.75.5-24.67%Buy
MRK$362.27B423.36.52.05.0-73.98%Hold

Smart narrative

XORTX Therapeutics Inc trades at $1.04. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -14.19, it sits in the distress.

Frequently asked questions

What is XORTX Therapeutics Inc's stock price?

XORTX Therapeutics Inc (XRTX) trades at $1.04.

Is XORTX Therapeutics Inc overvalued?

XORTX Therapeutics Inc carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of XORTX Therapeutics Inc (XRTX)?

The 12-month analyst consensus target is $14.04, about 1250.0% above the current $1.04. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

XORTX Therapeutics Inc's Altman Z-Score is -14.19, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio—
ROE-213.89%
Beta0.81
50D MA$1.49
200D MA$2.04
Shares out0.00B
Float0.00B
Short ratio—
Avg volume1.0M

Performance

1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—